Dermira to Report Second Quarter 2019 Results and Host Conference Call on Wednesday, August 7, 2019
July 31 2019 - 4:05PM
Business Wire
Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company
dedicated to bringing biotech ingenuity to medical dermatology by
delivering differentiated, new therapies to the millions of people
living with chronic skin conditions, will report financial results
for the quarter ended June 30, 2019 and provide an operational
update after market close on Wednesday, August 7, 2019. The company
will host a conference call and an audio webcast at 1:30 p.m.
Pacific Time (4:30 p.m. Eastern Time) on the same day.
Conference Call Information:
Domestic callers:
866-211-3117
International callers:
647-689-6606
Passcode:
3394726
Webcast information: Visit http://investors.dermira.com.
A webcast replay will be available on the Dermira website for 30
days.
About Dermira
Dermira is a biopharmaceutical company dedicated to bringing
biotech ingenuity to medical dermatology by delivering
differentiated, new therapies to the millions of patients living
with chronic skin conditions. Dermira is committed to understanding
the needs of both patients and physicians and using its insight to
identify, develop and commercialize leading-edge medical
dermatology products. The company’s approved treatment, QBREXZA™
(glycopyrronium) cloth, is indicated for pediatric and adult
patients (ages 9 and older) with primary axillary hyperhidrosis
(excessive underarm sweating). Please see the QBREXZA prescribing
information. Dermira is evaluating lebrikizumab for the treatment
of moderate-to-severe atopic dermatitis (a severe form of eczema)
and plans to initiate a Phase 3 clinical development program by the
end of 2019, subject to an end-of-Phase 2 meeting with the U.S.
Food and Drug Administration. Dermira also has early-stage research
and development programs in other areas of dermatology. Dermira is
headquartered in Menlo Park, Calif. For more information, please
visit http://www.dermira.com. Follow Dermira on Twitter, LinkedIn
and Instagram.
In addition to filings with the Securities and Exchange
Commission (SEC), press releases, public conference calls and
webcasts, Dermira uses its website (www.dermira.com), LinkedIn page
(https://www.linkedin.com/company/dermira-inc-), corporate
Instagram account (https://www.instagram.com/dermira_inc/) and
corporate Twitter account (@DermiraInc) as channels of distribution
of information about its company, product candidates, planned
financial and other announcements, attendance at upcoming investor
and industry conferences and other matters. Such information may be
deemed material information and Dermira may use these channels to
comply with its disclosure obligations under Regulation FD.
Therefore, investors should monitor Dermira’s website, LinkedIn
page, Instagram and Twitter accounts in addition to following its
SEC filings, news releases, public conference calls and
webcasts.
Forward-Looking Statements
The information in this news release contains forward-looking
statements and information within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, which are subject to
the “safe harbor” created by those sections. This news release
contains forward-looking statements that involve substantial risks
and uncertainties, including statements with respect to Dermira’s
goal of bringing biotech ingenuity to medical dermatology by
delivering differentiated, new therapies to the millions of
patients living with chronic skin conditions and Dermira’s plans to
initiate a Phase 3 development program for lebrikizumab by the end
of 2019, subject to an end-of-Phase 2 meeting with the U.S. Food
and Drug Administration. These statements deal with future events
and involve known and unknown risks, uncertainties and other
factors that may cause actual results, performance or achievements
to be materially different from the information expressed or
implied by these forward-looking statements. Factors that could
cause actual results to differ materially include risks and
uncertainties such as those relating to Dermira’s dependence on
third-party clinical research organizations, manufacturers,
suppliers and distributors; the design and implementation of
Dermira’s clinical trials; the outcomes of future meetings with
regulatory agencies; Dermira’s ability to attract and retain key
employees; Dermira’s ability to manage the growth and complexity of
its organization; Dermira’s ability to maintain, protect and
enhance its intellectual property; and Dermira’s ability to
continue to stay in compliance with its material contractual
obligations, applicable laws and regulations. You should refer to
the section entitled “Risk Factors” set forth in Dermira’s Annual
Report on Form 10-K, Dermira’s Quarterly Reports on Form 10-Q and
other filings Dermira makes with the SEC from time to time for a
discussion of important factors that may cause actual results to
differ materially from those expressed or implied by Dermira’s
forward-looking statements. Furthermore, such forward-looking
statements speak only as of the date of this news release. Dermira
undertakes no obligation to publicly update any forward-looking
statements or reasons why actual results might differ, whether as a
result of new information, future events or otherwise, except as
required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190731005837/en/
Media: Erica Jefferson Vice President, Corporate Communications
650-421-7216 media@dermira.com Investors: Andrew Guggenhime Chief
Financial Officer 650-421-7200 investor@dermira.com
Journey Medical (NASDAQ:DERM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Journey Medical (NASDAQ:DERM)
Historical Stock Chart
From Apr 2023 to Apr 2024